The Pfizer and Gilead-backed immuno-oncology therapy developer, which had raised $300m in an April series A round, floated at the top of its range.
Allogene Therapeutics, a US-based cancer drug developer that counts Pfizer and Gilead Sciences among its investors, raised $324m in an initial public offering on the Nasdaq Global Select Market yesterday.
The offering consisted of 18 million shares priced at $18.00 each, at the top of its $16 to $18 range, giving Allogene a market capitalisation of approximately $2.07bn. The company’s shares closed at $25.00 yesterday at the end of its first day of trading.
Founded earlier this year, Allogene…
